Evaluation of response to chemotherapy in patients affected with non-small cell lung cancer by means of three tumour markers elaborated by discriminant analysis

摘要: Chemotherapy is the most effective treatment for inoperable patients (70%) affected with non-small cell lung cancer (NSCLC). The early detection of tumour progression mandative in order to promptly shift these towards salvage or supportive therapy. present authors investigated clinical value a panel markers, elaborated by means discriminant analysis, as follow-up indicator progression. serum levels tissue polypeptide antigen (TPA), CYFRA-21.1, neuron-specific enolase (NSE) and carcino-embryonic (CEA) were determined before chemotherapy after three cycles treatment. Discriminant analysis generated formula (canonic variable) which correctly classified 87.8% 74 subjects (86.1% 36 progressive diseases 89.5% 38 non-progressive diseases). This approach produces an algorithm able calculate score NSCLC can be helpful following-up care therapy control patients.